All posts by imreal

Tabitha Ilges’s newly released “God’s Majesty” is a vibrant work that pairs vivid imagery with an eloquent poem


News Image

“God’s Majesty”: a charming poetic work. “God’s Majesty” is the creation of published author Tabitha Ilges.

Ilges shares, “God’s glory and majesty is indeed all around us. We can see his work in our everyday life. Every time we see trees sway or look up at the stars in the sky, sit in the shade beneath a cherry blossom tree or climb a mountain, we are witnesses to God’s handiwork.

“The poem that is the story of this book touches on some of God’s creation that we can witness his majesty through. Have you ever dipped your foot into a cool mountain spring on a hot summer day or hiked a trail over rocks and roots, and looked upon and listened to the roaring of a beautiful waterfall? Have you ever laid out at night and looked at the stars? If so, then you have witnessed the majesty of God. I hope you can find yourself encompassed in realization and appreciation for the glorious creation that surrounds us and realize that the majesty that is in them is from the hand of God.”

Published by Christian Faith Publishing, Tabitha Ilges’s new book will inspire readers in their faith as the myriad beauty of creation is explored.

Ilges shares in hopes of bringing readers a renewed sense of appreciation for the natural world.

Consumers can purchase “God’s Majesty” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “God’s Majesty,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

A Testimony to the Power of Prayer” is an engaging juvenile fiction with a mix of fantasy and faith


News Image

“The Journey Home: A Testimony to the Power of Prayer”: an enjoyable fantasy adventure that finds angels and fairies working together. “The Journey Home: A Testimony to the Power of Prayer” is the creation of published author Kim Michelle Gerber, a native of Australia and mother of two who now resides in Charleston, South Carolina, with a loving husband.

Gerber shares, “Kelly, a mother who has been estranged from her daughters for three long years, is about to find help from a very unexpected place!

“Her constant prayers for her two daughters, Shayla and Summer, have finally reached Heaven, and the creatures of the woods near her cottage home have been called in by the Great One to help fight the battle for her daughters’ souls.

“Fairies and owls, alongside the angels, formulate a plan to free the two college students and two college campuses from the demons that hold them and endeavor to bring the two girls back home to Him and to the mother who loves them.”

Published by Christian Faith Publishing, Kim Michelle Gerber’s new book will entertain and delight the imagination as Gerber paints a vivid world for all to enjoy.

Consumers can purchase “The Journey Home: A Testimony to the Power of Prayer” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “The Journey Home: A Testimony to the Power of Prayer,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

What It Means to Become a Friend of God” is an enjoyable guide to fully understanding mankind’s connection to God


News Image

“The Greatest Of These: What It Means to Become a Friend of God”: a heartwarming discussion of the fulfillment one can find in being a friend of God. “The Greatest Of These: What It Means to Become a Friend of God” is the creation of published author Curtis Wilson, a dedicated husband and father of two who retired from a successful business career to work in apostolic ministry for over twenty years.

Wilson shares, “One of the most unique aspects of Christianity is that the Creator of the universe draws us, the created, into a place of close relationship with himself. If you and I stopped at this point, it is quite certain that God has done more than we deserve. But God does not leave us to ourselves, even at the early stages of our born-again experience. He beckons each of us to live an existence that not only includes him but encompasses the kingdom through every part of our being.

“This is the place of close relationship that Jesus told his disciples they would experience. It is the place of moving past just working for God and becoming a friend of God. This book will give you tools to understand the process, steps for you to get there, and how to live it out each day.”

Published by Christian Faith Publishing, Curtis Wilson’s new book will challenge readers in their spiritual understanding as they are motivated to seek a stronger connection with God.

Wilson shares an encouraging study of one’s connection with God in a manner that will resonate with many seeking spiritual guidance.

Consumers can purchase “The Greatest Of These: What It Means to Become a Friend of God” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “The Greatest Of These: What It Means to Become a Friend of God,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

$54 Billion U.S. In Vitro Diagnostics (IVD) Market to See Growth in Point-of-Care (POC)


The most dynamic IVD segments in the U.S. market include microbiology, molecular diagnostics, and histology.

On a global regional scale, the U.S. market dominates the in vitro diagnostics (IVD) industry, according to the latest report by leading medical market research firm Kalorama Information. In 2022, the U.S. occupies 42% and about $54 billion of the global market for IVD products. This major IVD market is in a state of flux, trying to manage a myriad of issues, all of which collide with a huge system that costs more than any other in the world. The findings were featured in the research report “United States Market for In Vitro Diagnostic (IVD) Tests, 4th Edition.”

The leading growth rates for molecular diagnostics and histology out of all segments in the U.S. IVD market are products of their roles in rapid and sensitive pathogen detection, accurate viral load monitoring, and from risk assessment through tumor monitoring in oncology. Cancer represents one of the most burdensome diseases on the U.S. healthcare system. Demographic aging in the United States will continue to increase nationwide cancer incidence.

The point-of-care (POC) diagnostics market represents the largest IVD segment in the United States; consisting of both the POC diabetes segment ($8,617 million, 2022) and the POC non-diabetes segment ($11,996 million, 2022), which includes infectious diseases (such as COVID-19). The large market segment reflects the diversity of diagnostic technologies that migrated to near-patient settings and the importance of POC testing for preventative care; not to mention the strong demand for COVID-19 POC tests over the past two years.

The third- and fourth-largest U.S. IVD segments, immunoassay infectious disease and molecular microbiology, were certainly buoyed by the need for COVID-19 testing. The majority of immunoassay testing volume in the United States is run on core lab immunoassay analyzers or combined immunochemistry instruments.

Molecular diagnostics are uniquely responsive to infectious disease threats in the United States. Market growth for molecular infectious disease tests in the United States exploded in 2020 and has carried through to 2022 due to the pandemic.

Rising analytical speeds in sequencing allows for the rapid development of new probe and primer reagents for use in molecular test kits. Future clinical molecular assays for infectious disease may directly incorporate sequencing due to the technology’s ability to openly read pathogenic genomes for new resistance genes and other traits significant in therapy decisions.

Market performance between U.S. IVD segments has been inconsistent due to the pandemic. Core lab market segments in the United States are projected to grow by a little more than 1.1% through 2027.

In wider context, the United States remains the core geographical IVD market in the world at over $54 billion in sales or approximately 42% of the global market. Market growth in some segments in the United States has been accelerated due to the pandemic and the need for testing for COVID-19. The U.S. IVD market is projected by Kalorama Information to reach over $59 billion in 2027.

For more insights and information, purchase “United States Market for In Vitro Diagnostic (IVD) Tests, 4th Edition” on our website.

Share article on social media or email:

13 new non-ferrous luminaire options for MRI and beyond


Kenall has introduced ten new non-ferrous MedMaster troffers and three new slot luminaires with a variety of configurations, all designed for your challenging applications.

According to urban.org, the number of Americans ages 65 and older will more than double between 2000 and 2040. This uptick in demand for health care diagnostic procedures by an aging population means an increased need for non-ferrous lighting options in healthcare spaces. As a result, Kenall has introduced ten new non-ferrous MedMaster troffers and three new slot luminaires with a variety of configurations, all designed for your challenging applications.

For MRI suites, hybrid ORs, and other healthcare spaces where magnets are employed, Kenall offers the MedMaster MRI4SEDI and MRI4SESI Series. These luminaires come in a broad range of lumen packages and include an option for 530nm green to enhance the visibility of screens and monitors during surgeries. The increasingly popular MedMaster MedSlot Series now includes MRIRS4, a slim, stylish non-ferrous luminaire.

For cleanrooms and clean spaces in healthcare facilities, labs, and pharmacies, SimpleSeal NFCSEDI & NFCSESI luminaire families combine the best in non-ferrous construction and sealed performance to illuminate spaces where magnetically sensitive processes are performed, and EMI is of concern. Lynn Walldorf, Kenall’s Product Marketing Manager, said, “Our years of expertise in lighting challenging environments, especially in healthcare and cleanrooms, means your application will be safely and completely sealed from both sides — the room and the plenum – not just the room side. Also, our proprietary optics promote eye comfort, and reduce the debilitating glare in reflective surfaces, which is common with lower-quality flat-panel lighting.” Walldorf concluded, “As with all our lighting, the comfort of room occupants is always an important priority.”

About Kenall

Kenall Manufacturing, an independent sector of Legrand, was founded in Chicago, Illinois in 1963 and has built a reputation for durable lighting solutions of superior quality and exceptional value. Today, the company creates unique solutions for the healthcare, cleanroom/containment, food processing, transportation, high abuse, and correctional lighting markets. Kenall luminaires are designed in Kenosha, Wisconsin, and comply with the Buy American Act (manufactured in the United States with more than 50% of the component cost of US origin). For additional information, visit http://www.kenall.com.

Share article on social media or email:

Events, Fundraisers and Heightened Awareness Mark the 11th Annual Breast Reconstruction Awareness Day on Oct. 19, 2022


News Image

The American Society of Plastic Surgeons (ASPS), in partnership with The Plastic Surgery Foundation (PSF), is proud to announce the 11th annual Breast Reconstruction Awareness Day on Oct. 19, 2022.

Many women who undergo a mastectomy or lumpectomy are unaware of the breast reconstruction options available to them. Recognizing that patients deserve accurate information to make the best decisions impacting their care, ASPS and The PSF launched the Breast Reconstruction Awareness Campaign and the annual Breast Reconstruction Awareness (BRA) Day USA in 2012. BRA Day is designed to put an end to the unknowns surrounding breast reconstruction by promoting public education, patient care and research. BRA Day events worldwide bring much-needed attention to these procedures and provide information to patients and their supporters.

“When a breast cancer patient is facing a difficult change in her life, we want to engage, educate, and empower patients to make the choice that’s best for them, which includes knowing their breast reconstruction options,” said The Plastic Surgery Foundation President Bernard Lee, MD, MBA, MPH. “Breast Reconstruction Awareness Day helps us to do that.”

BRA Day efforts include informing patients, family, caregivers, and media that the breast cancer loop remains open until a woman is aware of her breast reconstruction options. Local BRA Day events are scheduled throughout the nation on Oct. 19, and both the ongoing campaign and events raise funds to support research and grants in local communities and nationally.

This campaign would not be possible without our sponsors and supporters, including Diamond Sponsor Allergan Aesthetics, an AbbVie company, Gold Sponsor Motiva/Establishment Labs, Bronze Sponsors CareCredit and the Integra Foundation. Through their continued commitment to patients, the BRA campaign has already raised approximately $175,000! Many regional and local events have committed to sharing a percentage of their dollars raised to the National Fund to support research, charitable care and awareness grants.

Supporters who would like to contribute have several options available throughout October. The CareCredit donation program will continue through the end of the month. Every time a CareCredit cardholder purchases $200 or more with their card at an ASPS-member location in the CareCredit network, CareCredit will donate $1 to the Breast Reconstruction Awareness campaign. The Breast Reconstruction Awareness 5K will take place Oct. 29 in Boston during Plastic Surgery The Meeting 2022. Participants can choose to run in person or virtually! Visit https://p2p.onecause.com/bra5k to learn more and sign up today.

About Breast Reconstruction

Breast reconstruction is part of a comprehensive approach and treatment for breast cancer patients. Studies show that women who undergo breast reconstruction experience significant improvements in psychological, social and sexual well-being. Every patient deserves to learn about breast reconstruction options at the time of diagnosis. The two main reasons women do not undergo breast reconstruction are that patients are not referred to breast reconstructive surgeons and are not informed of their reconstructive options.

This team approach provides a cohesive breast cancer treatment plan. Integral to this cohesiveness is the frequent breast tumor board meetings to discuss each patient and their individualized treatment. This group of specialists comprises breast surgeons, plastic pathologists, reconstructive surgeons, oncologists, radiation oncologists, radiologists, geneticists, nurses, patient care coordinators and more. This team approach ensures that all team members discuss and agree upon critical decisions regarding each patient’s treatment. All aspects of care, from social to medical, are addressed at these meetings.

For more information on breast reconstruction, visit http://www.breastreconusa.org. Become educated and help educate others about the availability of breast reconstruction and why all women deserve a team approach to breast cancer treatment.

About ASPS

The American Society of Plastic Surgeons (ASPS) is the largest organization of board-certified plastic surgeons in the world. Representing nearly 8,000 physician members, the society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery. ASPS comprises more than 92 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada.

About The PSF

The Plastic Surgery Foundation (The PSF), founded in 1948, supports research, international volunteer programs and visiting professor programs. The foundation’s mission is to improve the quality of life of patients through research and development. The PSF accomplishes its mission by providing invaluable support to the research of plastic surgery sciences through a variety of grant programs. The PSF works in concert with the American Society of Plastic Surgeons (ASPS).

###

Contact ASPS

Amy Hughes

Director of Public Relations and Communications

847.228.3333

ahughes@plasticsurgery.org

Share article on social media or email:

EDPMA Files Amicus Brief Holding Federal Regulators Accountable To Implement the No Surprises Act As Required By Law


News Image

EDPMA fully supports claims in the TMA lawsuit that simply ask that the No Surprises Act be followed as written so that the arbitrators charged with resolving payment disputes would not anchor the payment amount to the QPA and that their decision making is rooted in the statute.

The Emergency Department Practice Management Association (EDPMA) filed an amicus brief today in support of the Texas Medical Association (TMA), Dr. Adam Corley and Tyler Regional Hospital, LLC’s lawsuit against federal regulators challenging the implementation of the No Surprises Act (Rule) that clearly favors health plans.

Last fall, EDPMA, and the Virginia and Texas College of Emergency Physicians filed an amicus brief in support of TMA’s first lawsuit challenging federal regulators on the process to resolve reimbursement disputes between insurance plans and physicians, with special emphasis on the adverse effects the Rule threatens on the delivery of emergency care. The TMA plaintiffs won this lawsuit.

The court ruled that the NSA was not ambiguous and required that all the factors listed in the statute should be considered in determining the final payment amount. In the settled TMA case, the court clearly stated that the methodology used by health plans to calculate the QPA was incompatible with the No Surprises Act.

However, nothing really changed regarding how arbitrators resolved billing disputes between healthcare plans and physicians. In fact, arbitrators continue to unfairly skew independent dispute resolution (IDR) results in favor of insurers.

“EDPMA fully supports claims in the TMA lawsuit that simply ask that the No Surprises Act be followed as written so that the arbitrators charged with resolving payment disputes would not anchor the payment amount to the QPA and that their decision making is rooted in the statute. If the current final rule and de-facto benchmark standard goes unchecked, these practices go unchecked, emergency medicine physicians, their practices and their value as our nation’s healthcare safety net are in jeopardy. Access to emergency care – which was vital to assisting our country through the pandemic – will be compromised with fewer resources to emergency care while the health plans then and now continue to post record profits,” says Don Powell, DO, FACEP, EDPMA Chair of the Board.

EDPMA will continue to advocate for emergency medicine physicians and their practices to ensure fair reimbursement to protect patients and their in-network choices.

About EDPMA:

EDPMA is the nation’s only professional physician trade association focused on the delivery of high quality, cost-effective care in the emergency department. EDPMA’s membership includes emergency medicine physician groups of all sizes, as well as billing, coding, and other professional support organizations that assist healthcare providers in our nation’s emergency departments. Together, EDPMA’s members deliver or directly support health care for approximately half of the 146 million patients that visit U.S. emergency departments each year.

Share article on social media or email:

Computer Market Research Announces the Release of its New Co-op/MDF Program for Distributors.


“What we appreciate the most is CMR’s flexibility in customizing their products for our needs. The whole company is focused on making sure that we get the information we need to be successful.”-Buffalo Technology

[Las Vegas, Nevada] – Computer Market Research is excited to announce the release of its new Co-op/MDF program for distributors, a powerful web-based channel management program that will help distributors effectively manage and track their Co-op/MDF funds from vendors. The official launch date for its new program is October 1st, 2022.

Computer Market Research believes this program will make managing Co-op/MDF funds easier for distributors by eliminating the manual process of using excel spreadsheets.

Key Features:


  • Tracks marketing funds
  • Provides custom analytics
  • Improves tracking and monitoring of account usage
  • Helps monitor ROI
  • Allows unlimited users
  • Ensures accuracy
  • Ensures complete data integrity
  • Ensures expiring funds are used in a timely manner
  • Reduces costs – administrative time and expenses
  • Provides instant and secure access 24/7
  • Streamlines approvals and reimbursements
  • Expedites campaign implementation
  • Sends automatic e-mail notifications
  • Allows for multiple languages and currencies

All-In-One Solution

With Computer Market Research’s powerful web-based Co-op/MDF management program for distributors, this all-in-one solution will increase visibility, help actively engage distributors in the sales and marketing process, and ensure funds are put to better use. By saving time and eliminating paperwork, CMR’s Co-op/MDF management module allows partners the ability to review data in real-time, additionally sending automatic reminders to partners so that deadlines are kept.

About Computer Market Research

Computer Market Research has a long history of delivering cost-effective solutions that enable Global 5000 companies to more efficiently manage channel partnerships, optimize channel marketing programs, and recognize maximum value and ROI from the investments they make in their channels. For more information about Computer Market Research call (702) 247-1120 or visit http://www.ComputerMarketResearch.com.

###

Share article on social media or email:

US Fertility launches Research Division to further advance scientific and medical research in the field of reproductive medicine


US Fertility’s newly formed Research Division will conduct and publish high-quality research studies to advance the field of reproductive medicine.

Our Research Division celebrates the amazing contributions our research and education teams are making in collaboration across the US Fertility network, a network of innovation.

US Fertility’s newly formed Research Division will conduct and publish high-quality research studies to advance the field of reproductive medicine to provide better, more effective care to patients in the future.

US Fertility’s Research Division will be led by Kate Devine, M.D., Executive Medical Director and Chief Research Officer at US Fertility, in close collaboration with Luis Hoyos, M.D., Regional Research Director and practicing reproductive endocrinologist (REI) at US Fertility founding partner practice IVF Florida; Michael Homer, M.D., Regional Research Director and practicing REI at US Fertility founding partner practice, Reproductive Science Center of the San Francisco Bay Area (RSC); Meike Uhler, M.D., Regional Research Director and practicing reproductive endocrinologist (REI) at US Fertility founding partner practice Fertility Centers of Illinois (FCI); Samad Jahandideh, Ph.D., Head of Clinical Biostatistics at US Fertility, and others.    

US Fertility is the largest network of physician-owned and physician-led fertility practices in the nation. With more than 130,000 babies born to its credit, US Fertility completes more than 30,000 fresh IVF cycles annually, nearly 70,000 cycles total, include frozen embryo transfers, and performs 1,000+ elective and donor egg freezing cycles annually.

“Given our culture, commitment to excellence, incredible volume of data, and unparalleled talent, there’s no limit to what we can accomplish as a network,” shares Dr. Devine. “Our Research Division celebrates the amazing contributions our research and education teams are making in collaboration across the US Fertility network, a network of innovation.”

Dr. Devine is a practicing, board-certified reproductive endocrinologist and fertility physician at Shady Grove Fertility, a founding partner practice of US Fertility. Dr. Devine also serves as faculty to fellows at the National Institutes of Health (NIH) and to residents at Georgetown School of Medicine. Dr. Devine is the Quality Assurance Chair for the Society for Assisted Reproductive Technology (SART) as well as a Research Chair for the Society for Reproductive Endocrinology and Infertility (SREI). She serves on the Medical Executive Committee for the Jones Foundation and on the Editorial Board for Fertility and Sterility.

US Fertility’s Research Division announcement arrives as the organization gears up for a significant presence at the upcoming annual American Society for Reproductive Medicine (ASRM) Scientific Congress and Expo, which will take place from October 23-26, 2022, in Anaheim, California. Researchers from across the US Fertility network are showcasing abstracts, delivering oral presentations, and receiving research prizes during the event.

“Our team is hard at work educating the next generation of providers and embryologists to care for future patients struggling with infertility. 2022 represents the showing of some of our best research to date,” shares Dr. Devine. “I feel so privileged to work at an organization that values research and helps facilitate this amazing work.”

Visit the US Fertility Research Division landing page to learn more about the program and discover the latest research in the field of reproductive medicine. Contact usfresearchdivision@usfertility.com to become involved or to connect with the research team.

About US Fertility 

US Fertility is the nation’s largest partnership of physician-owned and physician-led top-tier fertility practices, offering comprehensive fertility-market-focused non-clinical, administrative, and technical platforms that help domestic and international practices improve patient outcomes and increase patient access. To learn more about partnership- or affiliate-status benefits, call 301-545-1308 or visit USFertility.com. 

Share article on social media or email:

FDA Allows Phase II-B Clinical Trial to Proceed Using Ischemic-Tolerant Mesenchymal Stem Cells to Treat Patients Suffering from Long-COVID


Pulthera is a US-based biopharmaceutical company focusing on the treatment and management of long COVID.

Long COVID is a significant health problem that has emerged in the wake of the pandemic. MSCs possess broad anti-inflammatory properties that may benefit the underlying condition.

Pulthera, LLC has received notice from the U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) that it can proceed with “A Phase 2b, Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of Intravenous Allogenic Bone Marrow-derived Mesenchymal Stem Cells in Subjects with Dyspnea Associated with Post-acute Sequelae of SARS-CoV-2 Infection.” The study will enroll up to 246 patients into two cohorts, randomized 1:1 to receive the active study drug plus standard treatment or placebo (lactate ringer solution) plus standard treatment, and will use MSCs manufactured by US-based Stemedica Cell Technologies.

Around 23 million people in the U.S. are living with long COVID, which is characterized by symptoms that continue after the initial viral infection for several weeks or more. An estimated 4 million people are unable to work due to the lingering symptoms and effects of long COVID. Because long COVID is such a new phenomenon and it’s not just one condition, it has been very difficult for physicians to effectively treat and manage the post-COVID conditions.

With the help of Rho, Inc., a leading global contract research organization, and protocol chief, Mark Nicolls, MD, who currently serves as Division Chief of Pulmonary, Allergy, and Critical Care Medicine at Stanford University, Pulthera will study the impact of MSCs as a therapeutic to aid those recovering from long COVID.

“Long COVID is a significant health problem that has emerged in the wake of the pandemic. Because long COVID presents in a number of ways that involve symptoms like shortness of breath, brain fog and fatigue, effective therapies are hard to design. MSCs possess broad anti-inflammatory and anti-fibrotic properties that may benefit the underlying condition,” says Nicolls.

The National Institutes of Health (NIH) has received $1 billion from Congress to run the largest research initiative on long COVID in the country, the Researching COVID to Enhance Recovery (RECOVER) initiative. Under the initiative, researchers will study the basic biology underlying long COVID and work on developing possible treatments. Earlier this year, Pulthera submitted a proposal to the NIH to participate in the RECOVER program as it seeks to develop treatments for those suffering from long COVID.

“The pandemic was very disruptive for many months, and we are now having to deal with the long-term impacts of COVID-19. We believe that there are regenerative and anti-inflammatory properties with MSC therapy that will positively impact patients suffering from dyspnea caused by long COVID,” said David Grieve, Founder and Chairman of Pulthera.

With the recent news, Pulthera is working to establish trial sites and clinics across the U.S. where patients can be evaluated and enroll in the clinical trial. Given the broad impact of long COVID, “we expect the study to move quickly and think we will see the positive outcomes MSCs provide to long COVID patients within the next year,” said Grieve.

About Pulthera, LLC

Pulthera, LLC is a US-based biopharmaceutical company focusing on the commercialization of “off the shelf” stem cell therapeutics designed to more effectively treat long COVID and potentially provide a strong defense against future pandemics. The Company has licensed the exclusive right to use, sell and distribute proprietary adult mesenchymal stem cells for all COVID-related and respiratory indications worldwide (some exclusions apply). Visit http://www.pulthera.com for more information about the Company.

About Stemedica Cell Technologies, Inc.

Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell, protein, and combination therapeutics for underserved medical conditions. Stemedica has developed a proprietary manufacturing technology platform that produces allogeneic progenitor cell products with intellectual property protection under a low-oxygen, low-tension environment in a cGMP-compliant manufacturing facility. The company’s lead drug candidate, ischemia-tolerant mesenchymal stem cells, or itMSCs, is an allogeneic progenitor cell therapy currently in clinical development for the treatment of ischemic stroke, COVID-19 and Alzheimer’s disease. The company’s second drug candidate, ischemia-tolerant neural progenitor cells, or itNSCs, is an allogeneic cell therapy currently in development for spinal cord injury. More information on Stemedica may be found at http://www.stemedica.com.

Share article on social media or email: